Skip to contentG
Gilead Sciences, Inc.
G
GILDGilead Sciences, Inc. Source filing unavailable
Q4 2015 · —
Revenue$8.51B$8.51B+16.3% vs Q4 2014 Net Income$4.68B$4.68B+34.3% vs Q4 2014 EPS Diluted$3.18$3.18+45.9% vs Q4 2014 Gross Profit$7,347,000,000+19.3% Operating Incomederived$5,621,000,000+29.8% The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Gilead Sciences, Inc. · CIK 882095 · Engraved from SEC EDGAR
Operating Cash Flowderived$5,795,000,000+91.8% Free Cash Flowderived$5,629,000,000+97.2% Margins · derivedGross margin86.4%+2.2 pt vs Q4 2014
Operating margin66.1%+6.9 pt vs Q4 2014
Net margin55.1%+7.4 pt vs Q4 2014